Table 3.

Response rates in JCAR014 in combination with durvalumab (NCT02706405) and JCAR014-alone cohorts (NCT01865617)

ORR – n (%), (95% CI)PCR – n (%), (95% CI)P
JCAR014 + durvalumab 9 of 26 (35), (19-54) .08∗  7 of 26 (27), (14-46) .09∗  
JCAR014 alone 6 of 12 (50), (25-75)  5 of 12 (42), (19-68)  
Group 1 4 of 9 (44), (19-73) .37†  4 of 9 (44), (19-73) .16†  
Group 2 5 of 17 (29), (13-53)  3 of 17 (18), (6-41)  
Group 2 5 of 17 (29), (13-53) .07∗  3 of 17 (18), (6 -41) .03∗  
JCAR014 alone 6 of 12 (50), (25-75)  5 of 12 (42), (19-68)  
Group 1 4 of 9 (44), (19-73) .50∗  4 of 9 (44), (19-73) .70∗  
JCAR014 alone 6 of 12 (50), (25-75)  5 of 12 (42), (19-68)  
ORR – n (%), (95% CI)PCR – n (%), (95% CI)P
JCAR014 + durvalumab 9 of 26 (35), (19-54) .08∗  7 of 26 (27), (14-46) .09∗  
JCAR014 alone 6 of 12 (50), (25-75)  5 of 12 (42), (19-68)  
Group 1 4 of 9 (44), (19-73) .37†  4 of 9 (44), (19-73) .16†  
Group 2 5 of 17 (29), (13-53)  3 of 17 (18), (6-41)  
Group 2 5 of 17 (29), (13-53) .07∗  3 of 17 (18), (6 -41) .03∗  
JCAR014 alone 6 of 12 (50), (25-75)  5 of 12 (42), (19-68)  
Group 1 4 of 9 (44), (19-73) .50∗  4 of 9 (44), (19-73) .70∗  
JCAR014 alone 6 of 12 (50), (25-75)  5 of 12 (42), (19-68)  
∗

P value per 1-sample proportion test (1-sided).

†

P value per Fisher exact test (1-sided).

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal